Table 1.
Patient demographics and clinical characteristics.
| Subjects characteristics | PT0, n = 11 | PT1, n = 11 | HD, n = 11 | P value |
|---|---|---|---|---|
| Age, years, mean (SD) | 71.27 (5.51) | 71.27 (5.51) | 67.0 (9.4) | P = 0.21∗ |
| Male, n (%) | 8 (72.72) | 8 (72.72) | 9 (81.81) | P = 0.62# |
| Former smokers, n (%) | 9 (81.8) | 9 (81.8) | 8 (72.72) | P = 0.62# |
| FVC, ml, mean (SD) | 2343.6 (777.88) | 2385.45 (801.51) | 0.6328§ | |
| FVC, % predicted, mean (SD) | 81.04 (26.95) | 77.90 (24.49) | 0.1813§ | |
| FEV1/FVC ratio, %, mean (SD) | 92.81 (4.43) | 91.66 (6.66) | 0.7161§ | |
| DLCO, % predicted, mean (SD) | 54.17 (18.11) | 56.1 (22.38) | 0.5770§ |
PT0, Pirfenidone T0, which refers to untreated patients just diagnosticated with IPF; PT1, Pirfenidone T1, which refers to IPF patients treated with Pirfenidone for 24 weeks; HD, healthy donors, which refers to healthy blood donors; FVC, forced vital capacity; FEV1, forced expiratory volume1; DLCO, carbon monoxide diffusing lung capacity. §P values were determined by paired t-test (PT0 versus PT1), ∗unpaired t-test (HD versus PT0/PT1), and #Chi-square (HD versus PT0/PT1).